Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, Hasbini A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Lange C, Phan L, Belhouari H, Tran Y, Kotti S, Helissey C. Oudard S, et al. Among authors: houede n. JAMA Oncol. 2023 Dec 1;9(12):1629-1638. doi: 10.1001/jamaoncol.2023.4255. JAMA Oncol. 2023. PMID: 37883073
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E. Schmitt A, et al. Among authors: houede n. Clin Cancer Res. 2009 May 15;15(10):3633-9. doi: 10.1158/1078-0432.CCR-09-0017. Epub 2009 Apr 28. Clin Cancer Res. 2009. PMID: 19401344 Clinical Trial.
Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old.
Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, Houéde N, Roy C, Durand X, Varinot J, Vordos D, Rouanne M, Bakhri MA, Bertrand P, Jeglinschi SC, Cussenot O, Soulié M, Pfister C. Compérat E, et al. Among authors: houede n. Virchows Arch. 2015 May;466(5):589-94. doi: 10.1007/s00428-015-1739-2. Epub 2015 Feb 20. Virchows Arch. 2015. PMID: 25697540
[Impacts of routine patient-reported-outcomes monitoring in oncology].
Fiteni F, Favier M, Bascoul-Mollevi C, Gourgou S, Cousin C, Houédé N. Fiteni F, et al. Among authors: houede n. Bull Cancer. 2018 Sep;105(9):847-848. doi: 10.1016/j.bulcan.2018.06.010. Epub 2018 Jul 20. Bull Cancer. 2018. PMID: 30032955 French. No abstract available.
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Joly F, Delva R, Mourey L, Sevin E, Bompas E, Vedrine L, Ravaud A, Eymard JC, Tubiana-Mathieu N, Linassier C, Houede N, Guillot A, Ringensen F, Cojocarasu O, Valenza B, Leconte A, Lheureux S, Clarisse B, Oudard S. Joly F, et al. Among authors: houede n. BJU Int. 2015 Jan;115(1):65-73. doi: 10.1111/bju.12552. BJU Int. 2015. PMID: 24180479 Clinical Trial.
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I. Michaelson MD, et al. Among authors: houede n. J Clin Oncol. 2014 Jan 10;32(2):76-82. doi: 10.1200/JCO.2012.48.5268. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323035 Clinical Trial.
138 results